A phase 1 open-label randomized clinical trial of A, B, C HIV-DNA vaccine (HIVIS DNA) and modified vaccinia Ankara Chiang Mai Double Recombinant (MVA-CMDR) vaccine ± co-administration of Toll-like Receptor 4 agonist (within Cervarix® human papilloma vaccine) in adolescents and youth living with perinatally acquired HIV-1
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 24 Apr 2024 New trial record
- 06 Mar 2024 All participants are expected to complete the study by mid-October 2023, according to Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024